BamSEC and AlphaSense Join Forces
Learn More

Recursion Pharmaceuticals Inc. – Material Contracts

NASDAQ: RXRX    
Share price (11/6/26): $3.52    
Market cap (11/6/26): $2.192 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 10-Q 4 pages Eleventh Amendment to Office Lease
12/34/56
EX-10.3
from 10-Q 20 pages Certain Information, Marked by Brackets and Asterisks [***], Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Rna Foundation Model License Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Certain Information, Marked by Brackets and Asterisks [***], Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Amendment to Master Agreement
12/34/56
EX-10.1
from 10-Q 2 pages August 4, 2026 Tempus Ai, Inc. 600 W Chicago Ave, Ste. 510 Chicago, Il 60654 Attn: Legal Re: Amendment to Master Agreement Between Tempus Ai, Inc. and Recursion Pharmaceuticals, Inc. Dear Ryan
12/34/56
EX-10.3
from 10-Q 5 pages 2. Confidentiality
12/34/56
EX-10.2
from 10-Q 6 pages 3. Confidentiality
12/34/56
EX-10.1
from 10-Q 6 pages Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy
12/34/56
EX-10.35
from 10-K 38 pages Recursion Pharmaceuticals, Inc. $300,000,000 Sales Agreement
12/34/56
EX-10.19
from 10-K 10 pages Confirmatory Employment Letter
12/34/56
EX-10.16
from 10-K 8 pages November 5, 2025 Najat Khan, PH.D. C/O Recursion Pharmaceuticals, Inc. 41 S Rio Grande Street Salt Lake City, Ut 84101 Re: CEO Employment Terms Dear Najat
12/34/56
EX-10.14
from 10-K 5 pages Advisory Agreement
12/34/56
EX-10.13
from 10-K 6 pages Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy
12/34/56
EX-10.1
from 8-K 6 pages Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy
12/34/56
EX-10.39
from 10-K 39 pages Sales Agreement
12/34/56
EX-10.36
from 10-K 57 pages Research Collaboration Agreement Dated September 19, 2023 by and Between Exscientia Ai Ltd. and Merck Healthcare Kgaa
12/34/56
EX-10.35
from 10-K 16 pages Research Collaboration and Licence Option Agreement
12/34/56
EX-10.20
from 10-K 13 pages Separation Agreement and Release
12/34/56
EX-10.18
from 10-K 17 pages Transition Agreement and Release
12/34/56
EX-10.14
from 10-K 10 pages Confirmatory Employment Letter
12/34/56
EX-10.1
from 8-K 10 pages Institutional Shareholder Irrevocable Undertaking
12/34/56